The Aesthetics Advisor

About four months after being diagnosed with stage 3   colorectal cancer , Fred Evrard was told by his smiling doctor: “Mr. Evrard, you are cancer free.” A lot had happened in just four months. Stage 3 Colon Cancer Hit When His Body Was at Its Peak On Sept. 10, 2020, Fred Evrard, aged 48, experienced a devastating blow in his life—he was diagnosed with stage 3 colon cancer, and the tumor in his body reached 10 centimeters in length. The news came as a real surprise to Evrard, a strong athletic martial arts instructor. Evrard has been practicing martial arts since he was a child. Over the past few decades, he has been active in various fitness activities such as boxing, parkour, tai chi, qigong, and meditation, in addition to teaching martial arts classes. His body was in prime shape when he was diagnosed, weighing 70 kg (154 lbs) with only nine percent body fat. His lifestyle and diet were also extremely healthy in the eyes of ordinary people. Evrard has been a vegetarian for ...

A 2022 study published in The New England Journal of Medicine has yielded groundbreaking results after a monoclonal antibody successfully eradicated rectal cancer in all enrolled patients, ushering them into complete remission without resorting to chemotherapy, radiation, or surgical interventions. Dr. Andrea Cercek, one of the lead researchers, said, “It’s absolutely incredible. We didn’t expect it.  We’ve certainly never seen this before . It’s really what, you know, cancer doctors’ dreams are made of to see a response like this. Such incredible efficacy with really, almost no toxicity.” Twelve patients participated, with a median age of 54 and 62% being women. These individuals had advanced rectal cancer, which typically requires harsh treatments. Patients were administered dostarlimab, a specific type of monoclonal antibody, every three weeks for six months, avoiding the conventional, often debilitating treatments associated with their condition. Every participant experienced...

Colorectal cancer is the third most diagnosed cancer in both men and women in the United States. While overall incidence rates seem to be dropping, rates in people under 50 have increased by   1 to 2 percent yearly  since the mid-1990s. In addition, colorectal cancer is responsible for the second leading cause of cancer-related deaths when fatality numbers for both men and women are combined. Part of the challenge of diagnosing colorectal cancer is that it often does not present symptoms until it has spread. Once symptoms present, gastrointestinal (GI) tests are often completed to rule out other complications or causes. The good news is that colorectal cancer’s five-year relative   survival rate  is around 91 percent for localized cancers, meaning the cancer was caught early and did not spread to additional areas. If the cancer goes undetected and spreads to other areas of the body, these rates decline. What Are the Common Types of Colorectal Cancer? There are severa...